ArticleFrontiers in microbiology2026
Synergistic effect and resistance prevention activity of antimicrobial peptide MPX with Tulathromycin against
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Actinobacillus pleuropneumoniae - today's perspective on advances and challenges (2017- 2026).BMC veterinary research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The emergence and dissemination of multidrug-resistant Methods: To assess synergism, the minimum inhibitory concentrations (MICs) of MPX and Tul, both individually and in combination, were determined using the micro-broth dilution method and checkerboard assay. Time-kill assays were conducted to analyze antibacterial activity and kill rate by quantifying viable bacterial counts. The post-antibiotic effect (PAE) was calculated following exposure to 1-2 MIC of each drug alone and in combination. For resistance prevention analysis, serial passage experiments were performed over 30 generations under selective pressure at 1/4 MIC for each agent to monitor changes in MIC values. Additionally, the mutant prevention concentration (MPC) was measured to evaluate MPX's capacity to narrow the MSW of Tul against APP. Finally, the antimicrobial activity of MPX and Tul was assessed against resistant APP strains. Results and discussion: The fractional inhibitory concentration index (FICI) indicated an indifferent interaction (1.5) for susceptible strains and an additive effect (0.75) for resistant strains. Time-kill curves demonstrated that MPX significantly enhanced the antibacterial efficacy of Tul against APP. Specifically, the kill rate within 0-1 hour and the PAE at 1-2 MIC of Tul increased from 0.35-2.91 to 1.41-5.03 Log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.